02:34 AM EDT, 07/10/2026 (MT Newswires) -- Nexstim (NXTMH.HE) said Friday it secured Health Canada's approval for expanded indications of its NBS 6 system covering diagnostic applications and chronic neuropathic pain treatment. Under the expanded approval, the medical technology company can market and commercially distribute the NBS 6 for pre-procedural mapping of the speech and motor cortices of the brain, as well as for treating chronic neuropathic pain. NBS 6 was previously approved in Canada for the treatment of major depressive disorder in 2024.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.